Steinhauser Motta João Pedro, Kempa Axel Tobias, Pinto Cardoso Alexandre, Paschoal Marcos Eduardo, Raggio Luiz Ronir, Lapa E Silva José Roberto, Stanzel Franz
Instituto de Doenças do Torax, Universidade Federal do Rio de Janeiro, Rua Professor Rodolpho Paulo Rocco, 255, 1 andar, sala 01D 58/60, Rio de Janeiro, RJ, 21941-913, Brazil.
Klinikum-Stuttgart, Kriegbergstrasse 60, 70174, Stuttgart, Germany.
BMC Pulm Med. 2016 Jul 19;16(1):101. doi: 10.1186/s12890-016-0264-7.
Since the first articles published for over 10 years ago, endobronchial ultrasound (EBUS) has gained a strong scientific backing and has been incorporated into routine medical practice in pulmonology and thoracic surgery centers. How is EBUS performing outside the scientific environment, as a diagnostic and mediastinal staging tool in a subset of patients that undergo thoracic surgery, is an interesting question.
This study evaluated consecutive patients who, during the period from January 2010 to August 2012, were submitted to EBUS and later to thoracic surgery. The samples obtained by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) were compared to surgical samples. The primary endpoint was the proportion of patients with a final diagnosis of non-small cell lung cancer (NSCLC) by EBUS-TBNA correctly subtyped. The secondary endpoint was the negative predictive value (NPV) of EBUS-TBNA for mediastinal staging of lung cancer.
Two hundred eighty seven patients were studied. Considering 84 patients with a final diagnosis of NSCLC by EBUS-TBNA, 79 % (CI 95 % 70.1-87.3) were correctly subclassified. The NPV of EBUS-TBNA for mediastinal staging was 89 % (IC 95 % 84.9-92.7). From a total of 21 false negative cases of mediastinal staging, 16 (76 %) did not undergo positron emission tomography-computed tomography (PET-CT) before the EBUS and in 15 (71 %) the affected lymph node chain was not punctured by EBUS-TBNA. Ten (47 %) patients had only lymph node metastases not directly accessible by the EBUS.
Performed in hospital routine and in patients submitted to thoracic surgery, EBUS-TBNA proved to be a good tool for proper pathological diagnosis of lung cancer. The negative predictive value of 89 % for mediastinal staging of lung cancer is comparable to that reported in previous studies, but the relatively high number of 21 false negative cases points to the need for standardization of routine strategies before, during and after EBUS.
自10多年前发表首批相关文章以来,支气管内超声(EBUS)已获得强有力的科学支持,并已被纳入肺科和胸外科中心的常规医疗实践。作为一种诊断和纵隔分期工具,EBUS在科学环境之外,在接受胸外科手术的一部分患者中的表现如何,是一个有趣的问题。
本研究评估了2010年1月至2012年8月期间连续接受EBUS检查并随后接受胸外科手术的患者。将支气管内超声引导下经支气管针吸活检(EBUS-TBNA)获取的样本与手术样本进行比较。主要终点是通过EBUS-TBNA最终诊断为非小细胞肺癌(NSCLC)且亚型分类正确的患者比例。次要终点是EBUS-TBNA对肺癌纵隔分期的阴性预测值(NPV)。
共研究了287例患者。在通过EBUS-TBNA最终诊断为NSCLC的84例患者中,79%(95%置信区间70.1-87.3)被正确分类。EBUS-TBNA对纵隔分期的NPV为89%(95%置信区间84.9-92.7)。在总共21例纵隔分期假阴性病例中,16例(76%)在EBUS检查前未进行正电子发射断层扫描-计算机断层扫描(PET-CT),15例(71%)受影响的淋巴结链未被EBUS-TBNA穿刺。10例(47%)患者仅有EBUS无法直接触及的淋巴结转移。
在医院常规和接受胸外科手术的患者中进行EBUS-TBNA,结果证明它是肺癌正确病理诊断的良好工具。EBUS对肺癌纵隔分期的阴性预测值为89%,与先前研究报告的结果相当,但21例假阴性病例数量相对较多,这表明需要对EBUS检查前、检查期间和检查后的常规策略进行标准化。